content: <?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:com="http://www.sec.gov/edgar/common">
    <headerData>
      <submissionType>144</submissionType>
      <filerInfo>
        <filer>
          <filerCredentials>
            <cik>0001799812</cik>
            <ccc>XXXXXXXX</ccc>
          </filerCredentials>
        </filer>
        <liveTestFlag>LIVE</liveTestFlag>
  
  
      </filerInfo>
    </headerData>
    <formData>
      <issuerInfo>
        <issuerCik>0001880438</issuerCik>
        <issuerName>AN2 Therapeutics, Inc.</issuerName>
        <secFileNumber>001-41331</secFileNumber>
        <issuerAddress>
          <com:street1>1800 EL CAMINO REAL, SUITE D</com:street1>
          <com:city>MENLO PARK</com:city>
          <com:stateOrCountry>CA</com:stateOrCountry>
          <com:zipCode>94027</com:zipCode>
        </issuerAddress>
        <issuerContactPhone>(650) 331-9090</issuerContactPhone>
        <nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>Adjuvant Global Health Technology Fund DE, L.P.</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
        <relationshipsToIssuer>
          <relationshipToIssuer>Shareholder</relationshipToIssuer>
        </relationshipsToIssuer>
      </issuerInfo>
      <securitiesInformation>
        <securitiesClassTitle>Common</securitiesClassTitle>
        <brokerOrMarketmakerDetails>
          <name>Merrill</name>
          <address>
            <com:street1>555 California Street</com:street1>
            <com:street2>Floor 18</com:street2>
            <com:city>San Francisco</com:city>
            <com:stateOrCountry>CA</com:stateOrCountry>
            <com:zipCode>94104</com:zipCode>
          </address>
        </brokerOrMarketmakerDetails>
        <noOfUnitsSold>15907</noOfUnitsSold>
        <aggregateMarketValue>332138.00</aggregateMarketValue>
        <noOfUnitsOutstanding>29741445</noOfUnitsOutstanding>
        <approxSaleDate>01/16/2024</approxSaleDate>
        <securitiesExchangeName>NASDAQ</securitiesExchangeName>
      </securitiesInformation>
      <securitiesToBeSold>
        <securitiesClassTitle>Common</securitiesClassTitle>
        <acquiredDate>11/20/2019</acquiredDate>
        <natureOfAcquisitionTransaction>Investment fund shares</natureOfAcquisitionTransaction>
        <nameOfPersonfromWhomAcquired>Issuer</nameOfPersonfromWhomAcquired>
        <isGiftTransaction>N</isGiftTransaction>
        <amountOfSecuritiesAcquired>15907</amountOfSecuritiesAcquired>
        <paymentDate>11/20/2019</paymentDate>
        <natureOfPayment>Cash</natureOfPayment>
      </securitiesToBeSold>
      <nothingToReportFlagOnSecuritiesSoldInPast3Months>N</nothingToReportFlagOnSecuritiesSoldInPast3Months>
      <securitiesSoldInPast3Months>
        <sellerDetails>
          <name>Adjuvant Global Health Technology Fund, L.P.</name>
          <address>
            <com:street1>C/O Adjuvant Capital, LP</com:street1>
            <com:street2>501 Fifth Avenue, Suite 1404</com:street2>
            <com:city>New York</com:city>
            <com:stateOrCountry>NY</com:stateOrCountry>
            <com:zipCode>10017</com:zipCode>
          </address>
        </sellerDetails>
        <securitiesClassTitle>Common</securitiesClassTitle>
        <saleDate>11/14/2023</saleDate>
        <amountOfSecuritiesSold>1522</amountOfSecuritiesSold>
        <grossProceeds>24574.21</grossProceeds>
      </securitiesSoldInPast3Months>
      <securitiesSoldInPast3Months>
        <sellerDetails>
          <name>Adjuvant Global Health Technology Fund DE, L.P.</name>
          <address>
            <com:street1>C/O Adjuvant Capital, LP</com:street1>
            <com:street2>501 Fifth Avenue, Suite 1404</com:street2>
            <com:city>New York</com:city>
            <com:stateOrCountry>NY</com:stateOrCountry>
            <com:zipCode>10017</com:zipCode>
          </address>
        </sellerDetails>
        <securitiesClassTitle>Common</securitiesClassTitle>
        <saleDate>11/14/2023</saleDate>
        <amountOfSecuritiesSold>288</amountOfSecuritiesSold>
        <grossProceeds>4650.04</grossProceeds>
      </securitiesSoldInPast3Months>
      <noticeSignature>
        <noticeDate>01/16/2024</noticeDate>
        <signature>Kabeer Aziz</signature>
      </noticeSignature>
    </formData>
  </edgarSubmission>
metadata_documents: [{"type": "144", "sequence": "1", "filename": "primary_doc.xml", "secsgml_size_bytes": 4156}]
text: 144
  0001799812
  XXXXXXXX
  LIVE
  0001880438
  AN2 Therapeutics, Inc.
  001-41331
  1800 EL CAMINO REAL, SUITE D
  MENLO PARK
  CA
  94027
  (650) 331-9090
  Adjuvant Global Health Technology Fund DE, L.P.
  Shareholder
  Common
  Merrill
  555 California Street
  Floor 18
  San Francisco
  CA
  94104
  15907
  332138.00
  29741445
  01/16/2024
  NASDAQ
  Common
  11/20/2019
  Investment fund shares
  Issuer
  N
  15907
  11/20/2019
  Cash
  N
  Adjuvant Global Health Technology Fund, L.P.
  C/O Adjuvant Capital, LP
  501 Fifth Avenue, Suite 1404
  New York
  NY
  10017
  Common
  11/14/2023
  1522
  24574.21
  Adjuvant Global Health Technology Fund DE, L.P.
  C/O Adjuvant Capital, LP
  501 Fifth Avenue, Suite 1404
  New York
  NY
  10017
  Common
  11/14/2023
  288
  4650.04
  01/16/2024
  Kabeer Aziz